ProQR raises $57.5 million

ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share.  All of the shares are being offered by ProQR.  The closing included the full exercise of the underwriters’ option to purchase up to 1,363,636 additional ordinary shares at the public offering price, less underwriting discounts and commissions.  Gross proceeds from the offering totaled approximately $57.5 million, before deducting underwriting discounts and commissions and offering expenses. 

Citigroup Global Markets and Evercore ISI acted as joint bookrunners for the offering.  Cantor Fitzgerald & Co. and JMP Securities acted as lead managers, with Chardan and Kempen acting as co-managers.

Source: ProQR (press release)